blind
randomized prospective one-center comparative placebo-
controlled clinical
trial is carried out
Agaverdiev, Murad,
Shamsov, Bedil,
Mirzoev, Sorbon,
Vardikyan, Andranik,
Encarnacion, Manuel Ramirez,
Nurmukhametov, Renat,
Beilerli, Aferin,
Zhang, Bohan,
Gareev, Ilgiz,
Pavlov, Valentin (2023) into two stages.
Results: By August 2022, there were 149 registered clinical
trials. Most studies belong
Zelinska, N.,
Iotova, V.,
Skorodok, J.,
Malievsky, O.,
Peterkova, V.,
Samsonova, L.,
Rosenfeld, Ron G.,
Zadik, Zvi,
Jaron-Mendelson, Michal,
Koren, Ronit,
Amitzi, Leanne,
Raduk, Dmitri,
Hershkovitz, Oren,
Hart, Gili (2017) : A multicenter, open-label,
randomized,
controlled phase 2 study in children with GHD,
evaluating
Chatelain, Pierre,
Malievskiy, Oleg,
Radziuk, Klaudziya,
Senatorova, Ganna,
Abdou, Magdy O.,
Vlachopapadopoulou, Elpis,
Skorodok, Yulia,
Peterkova, Valentina,
Leff, Jonathan A.,
Beckert, Michael (2017) children with GHD.
Design:
Randomized, open-label, active-
controlled study of three doses of weekly Trans